Robinson Samuel, Nag Alena, Peticca Benjamin, Prudencio Tomas, Di Carlo Antonio, Karhadkar Sunil
Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Department of Surgery, Temple University Hospital, Philadelphia, PA 19140, USA.
Cancers (Basel). 2023 Dec 19;16(1):3. doi: 10.3390/cancers16010003.
Kidney transplant patients have a higher risk of renal cell carcinoma (RCC) compared to non-transplanted end-stage kidney disease (ESKD) patients. This increased risk has largely been associated with the use of immunosuppression; however, recent genetic research highlights the significance of tissue specificity in cancer driver genes. The implication of tissue specificity becomes more obscure when addressing transplant patients, as two distinct metabolic environments are present within one individual. The oncogenic potential of donor renal tissue is largely unknown but assumed to pose minimal risk to the kidney transplant recipient (KTR). Our review challenges this notion by examining how donor and recipient microenvironments impact a transplant recipient's associated risk of renal cell carcinoma. In doing so, we attempt to encapsulate how ESKD-RCC and KTR-RCC differ in their incidence, pathogenesis, outcome, and approach to management.
与未接受移植的终末期肾病（ESKD）患者相比，肾移植患者患肾细胞癌（RCC）的风险更高。这种风险增加在很大程度上与免疫抑制的使用有关；然而，最近的基因研究突出了癌症驱动基因中组织特异性的重要性。在处理移植患者时，组织特异性的影响变得更加模糊，因为一个人体内存在两种不同的代谢环境。供体肾组织的致癌潜力在很大程度上尚不清楚，但假定对肾移植受者（KTR）构成的风险最小。我们的综述通过研究供体和受体微环境如何影响移植受者患肾细胞癌的相关风险，对这一观点提出了质疑。在此过程中，我们试图概括ESKD-RCC和KTR-RCC在发病率、发病机制、结局和管理方法上的差异。
Zotero 插件
